326 related articles for article (PubMed ID: 10762138)
1. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
Hirsch EC
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
[TBL] [Abstract][Full Text] [Related]
2. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
Anglade P; Tsuji S; Javoy-Agid F; Agid Y; Hirsch EC
Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
[TBL] [Abstract][Full Text] [Related]
3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
Calabresi P; Giacomini P; Centonze D; Bernardi G
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S60-8; discussion S68-9. PubMed ID: 10762133
[TBL] [Abstract][Full Text] [Related]
5. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
6. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
7. [Neuroplasticity and Parkinson disease].
Viallet F; Witjas T
Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S42-8. PubMed ID: 12690663
[TBL] [Abstract][Full Text] [Related]
8. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
Brotchie JM
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4. PubMed ID: 10762137
[TBL] [Abstract][Full Text] [Related]
9. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
Melamed E
Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
[No Abstract] [Full Text] [Related]
10. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
Melamed E; Hefti F
Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
[No Abstract] [Full Text] [Related]
11. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Guigoni C; Dovero S; Aubert I; Li Q; Bioulac BH; Bloch B; Gurevich EV; Gross CE; Bezard E
Eur J Neurosci; 2005 Jul; 22(1):283-7. PubMed ID: 16029219
[TBL] [Abstract][Full Text] [Related]
13. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
14. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
15. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
16. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
Brücke T; Riederer P
Wien Med Wochenschr; 1986 Aug; 136(15-16):401-8. PubMed ID: 2878540
[TBL] [Abstract][Full Text] [Related]
17. Dopamine-mediated gene regulation in models of Parkinson's disease.
Gerfen CR
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S42-50; discussion S50-2. PubMed ID: 10762131
[TBL] [Abstract][Full Text] [Related]
18. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
19. Clinical physiology of dopa dyskinesia.
Hallett M
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
[TBL] [Abstract][Full Text] [Related]
20. Preventing levodopa-induced dyskinesias.
Olanow CW; Obeso JA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
